Stock Market & Financial Investment News

News Breaks December 20, 2012 08:39 EDT DNDN, NVS Dendreon sells New Jersey facility to Novartis for $43M Dendreon (DNDN) sold its immunotherapy manufacturing facility based in Morris Plains, New Jersey, to Novartis (NVS) for $43M in cash. The facility features capabilities to manufacture Provenge (sipuleucel-T), the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. News For DNDN;NVS From The Last 14 Days Check below for free stories on DNDN;NVS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 16:20 EDT NVS Novartis drug Afinitor extended time without disease progression in women Subscribe for More Information May 16, 2013 08:11 EDT NVS Novartis says no intention of pursuing Actavis, Bloomberg reports Subscribe for More Information May 15, 2013 19:37 EDT NVS Novartis weighing Actavis bid, WSJ reports Subscribe for More Information 18:17 EDT NVS Novartis weighs possible bid for Actavis, DJ reports Subscribe for More Information May 10, 2013 10:00 EDT DNDN On The Fly: Analyst Downgrade Summary Subscribe for More Information 09:38 EDT DNDN Active equity option families trading Subscribe for More Information 09:21 EDT DNDN On The Fly: Pre-market Movers Subscribe for More Information 07:55 EDT DNDN Dendreon may generate near-term trading opportunity, says RW Baird Subscribe for More Information 07:44 EDT DNDN Dendreon price target lowered to $1 from $5 at BofA/Merrill Subscribe for More Information 07:40 EDT DNDN Dendreon price target lowered to $6.50 from $9 at Bernstein Subscribe for More Information 05:51 EDT DNDN Dendreon downgraded to Sell from Neutral at Citigroup Subscribe for More Information 05:42 EDT NVS Novartis drug Ilaris approved by FDA Subscribe for More Information May 9, 2013 14:15 EDT DNDN Dendreon downgraded to Sell from Neutral at Roth Capital Subscribe for More Information 13:32 EDT DNDN Dendreon downgraded to Sell from Hold at Stifel Subscribe for More Information 12:35 EDT DNDN On The Fly: Midday Wrap Subscribe for More Information 10:56 EDT DNDN Dendreon price target lowered to $3 from $4 at Maxim Subscribe for More Information 08:42 EDT DNDN Dendreon reports Q1 EPS (48c), consensus (48c) Subscribe for More Information May 6, 2013 16:23 EDT NVS Array to start first company-led Phase 3 trial with MEK162 Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. Sign up for a free trial to see the rest of the stories you've been missing.